Gastroenterologists' perspectives of high-dose dual therapy for Helicobacter pylori infection in China: Results of a China survey

中国胃肠病学家对幽门螺杆菌感染高剂量双联疗法的看法:一项中国调查的结果

阅读:1

Abstract

This study investigates the knowledge of the high-dose dual therapy (HDDT) in the eradication of Helicobacter pylori (H pylori) infection among gastroenterologists in China. A survey was conducted among gastroenterologists in China using the "Questionnaire Star," and the questionnaire link was sent by WeChat. Descriptive methods were used for statistical analysis. A total of 863 valid questionnaires were collected. The awareness rate of HDDT was 96.5%, and the clinical utilization rate was 69.1%.12.4%, 29.9%, and 25.6% gastroenterologists chose HDDT for the first-line, rescue and refractory treatment of H pylori infection. Amoxicillin was the most commonly used antibiotic in HDDT, followed by clarithromycin, furazolidone, levofloxacin, metronidazole, cefuroxime and tetracycline. Potassium-competitive acid blockers (51.8%) were the most commonly acid inhibitors in high-dose double therapy, followed by proton pump inhibitors and H2-receptor blockers. Most gastroenterologists believed that high-dose double therapy would become the main method of first-line and rescue treatment of H pylori infection. HDDT maybe the main treatment of H pylori eradication, but the application of the HDDT among gastroenterologists in China is insufficient. Better education should be carried out in future to improve the ability of gastroenterologists to standardize the treatment of H pylori infection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。